| DrugRepV_7840 | benzyl N-[(2S)-1-[[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[(4,4,4-trifluoro-3-oxo-1-phenylbutan-2-yl)amino]pentan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7841 | (4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-phenylmethoxybutanoyl]amino]-4-methylpentanoyl]amino]-N,N-dimethyl-6-(5-nitro-1,4-dioxo-3H-phthalazin-2-yl)-5-oxohexanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7842 | methyl (E,4S)-4-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]pentanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7843 | ethyl 3-[(3-amino-3-oxopropyl)-[[(2R,5S)-2-benzyl-7-methyl-4-oxo-5-(phenylmethoxycarbonylamino)octanoyl]amino]carbamoyl]oxirane-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7844 | (2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]propanoyl]amino]-N-[(2S)-3-cyclohexyl-1-[[(2S)-1-(1H-imidazol-5-yl)-3-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-3-methylbutanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7845 | N-[(Benzyloxy)carbonyl]valyl-N-[1-oxo-3-(2-oxo-3-pyrrolidinyl)-1-(1,3-thiazol-2-yl)-2-propanyl]leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7846 | N-[(Benzyloxy)carbonyl]-L-valyl-N-{(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-D-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7847 | N-{[3-(Dimethylamino)phenoxy]acetyl}-L-valyl-N-{(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7848 | 2-[2,3-Dichloro-4-(2-methylenebutanoyl)phenoxy]-N-(2-methyl-2-propanyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7849 | Cinanserin | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7850 | 5-Chloro-3-pyridinyl 1H-indole-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7851 | 1-(2-Naphthylmethyl)-2,3-dioxo-5-indolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7852 | 1-[(1H-Indol-5-ylcarbonyl)oxy]-1H-benzotriazole | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7853 | 4-(4-Chlorophenyl)-2-[(4-nitrobenzyl)sulfanyl]-6-oxo-1,6-dihydro-5-pyrimidinecarbonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7854 | 4-{(Z)-[1-(4-Fluorophenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene]methyl}benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7855 | 3-Benzyl-1-[(6,7-dimethyl-2-oxo-1,2-dihydro-3-quinolinyl)methyl]-1-[2-(2-methylphenyl)ethyl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7856 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N2-(3-methylbutanoyl)-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7857 | tert-butyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7858 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7859 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-1-oxohexan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7860 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7861 | Benzyl [(2S,3R)-1-({(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}amino)-3-methyl-1-oxo-2-pentanyl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7862 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7863 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7864 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-4-methyl-2-[(2-phenylacetyl)amino]pentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7865 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(4-methoxyphenyl)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7866 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[3-(4-methoxyphenyl)propanoylamino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7867 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N2-[3-(3-pyridinyl)propanoyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7868 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(2E)-3-phenyl-2-propenoyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7869 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(2E)-3-(4-methoxyphenyl)-2-propenoyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7870 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(2E)-3-(3,4-dimethoxyphenyl)-2-propenoyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7871 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-4-methyl-2-[(2-phenoxyacetyl)amino]pentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7872 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(4-methoxyphenoxy)acetyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7873 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(4-hydroxyphenoxy)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7874 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-{[3-(dimethylamino)phenoxy]acetyl}-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7875 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(4-methoxyanilino)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7876 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(3-methoxyanilino)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7877 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(2-methoxyanilino)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7878 | benzyl N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(5-phenyl-1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7879 | N~2~-[(Benzyloxy)carbonyl]-N-{(2S)-1-[5-(4-methylphenyl)-1,3-thiazol-2-yl]-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7880 | benzyl N-[(2S)-1-[[(2S)-1-[5-(4-methoxyphenyl)-1,3-thiazol-2-yl]-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7881 | benzyl N-[(2S)-1-[[(2S)-1-[5-(2-methoxyphenyl)-1,3-thiazol-2-yl]-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |